NETRAMARK ANNOUNCES GRANT OF BONUS SHARES, STOCK OPTIONS AND RSUS

TORONTO, ON, June 22, 2023 – NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV), announces today that it intends to issue 200,000 common shares of the Company as bonus shares (each, a "Bonus Share") to an officer of the Company on June 30, 2023, at a deemed price per share equal to the market price of the Common Shares on the day of issuance or such greater price as may be required by the policies of the Canadian Securities Exchange. The Bonus Shares will be subject to a four (4) month and a day hold period.

The Board approved the issuance of the Bonus Shares as compensation for the achievement of significant performance year-to-date.

The issuance of the Bonus Shares constitutes a "related party transaction" as this term is defined in Multilateral Instrument 61-101: Protection of Minority Securityholders in Special Transactions ("MI 61-101"). The Company is exempt from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101 as the fair market value of the Bonus Shares does not exceed 25% of the Company's market capitalization, as determined in accordance with MI 61-101. The Company did not file a material change report more than 21 days before the expected closing of the Bonus Shares transaction as the details and amounts of the bonuses were not finalized until closer to the closing and the Company wishes to close the transaction as soon as practicable, which the Company deems reasonable.

The Company has also granted an aggregate of 600,000 stock options (each, a "Stock Options") to certain directors, officers, and employees of the Company for the purchase of up to 600,000 common shares, pursuant to the Company's Stock Option Plan. The Stock Options are exercisable for a period of two years at an exercise price of CAD\$0.38 per share and vest 12.5% per quarter for two years following the date of grant.

The Company also granted an aggregate of 1,200,000 restricted share units (each, a "RSU") to certain directors and officers of the Company pursuant to the Company's equity incentive plan (the "Equity Incentive Plan"). The RSUs shall vest 12,5% per quarter for two years following the date of grant.

About NetraMark

NetraMark is a company focused on being a leader in the development of Artificial Intelligence (AI) / Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the

data, to transform the data into powerfully intelligent data that activates traditional AI / ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and / or efficacy of treatment.

For further details on the Company please see the Company's publicly available documents filed on the System for Electronic Document Analysis and Retrieval (SEDAR).

Company contact information: Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549

Forward-Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the issuance of the Bonus Shares which is based upon NetraMark's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors.

When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com including our Management's Discussion and Analysis for the year ended September 30, 2022. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.